Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.

ABSTRACT:

Background

The indications for fertility preservation (FP) have expanded. A few patients who underwent gonadotoxic treatment did not have the opportunity to receive FP, leading to concerns that these patients may develop premature ovarian insufficiency. However, the usefulness of FP in women with reduced ovarian reserve has also been questioned. Progestin-primed ovarian stimulation can improve the controlled ovarian stimulation (COS) protocol, but there is limited data on the efficacy of FP with progestin-primed ovarian stimulation.

Methods

We conducted a prospective study of 43 women with cancer or autoimmune diseases before and after gonadotoxic treatment at the reproductive unit of Keio University Hospital, counselled between 1 January 2018 and 31 December 2021. After cou

SUBMITTER: Saito S 

PROVIDER: S-EPMC10416401 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature